Select Your Region
Global
A study of the safety of a new medicine (DCLL9718S) in patients with a type of blood cancer (acute myeloid leukemia)
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Cancer Leukemia
Basic Details
All
≥ 18 Years
No
Sponsor
Genentech, Inc.
Phase
Phase 1
Study Identifier
NCT03298516, GO39902
This clinical trial was done to study a new medicine called, “DCLL9718S”, for the treatment of patients with “acute myeloid leukemia”, a type of blood cancer. Researchers wanted to find out what the safe dose of DCLL9718S was, and whether patients could tolerate the side effects. Researchers were also interested to find out if the study medicine had any effect on the cancer. Eighteen patients took part in this study at eight study centers in two countries.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
What you can do next
To find this study again later, copy and save the study number:
{{ctId}}
To see if this study is a good fit, talk to your doctor or nurse you trust.
Together, you can look at the For Medical Professional tab and look into your medical history.
Some medical centers in this study offer a contact line. Click "Find participating medical centers" in the map below.
For the latest version of this information please go to www.forpatients.roche.com